1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

Can the Addition of Radiolabeled Treatments Improve Outcomes in Advanced Metastatic Disease?

Radiolabeled agents are powerful tools for targeting and killing cancer cells and may help improve outcomes and lengthen survival times of patients with advanced disease that has spread beyond the initial tumor site.

 
 
Cancer Biotherapy and Radiopharmaceuticals
Cancer Biotherapy and Radiopharmaceuticals
PRLog - Nov. 13, 2012 - Contact: Vicki Cohn, Mary Ann Liebert, Inc, (914) 740-2100, ext. 2156, vcohn@liebertpub.com

Can the Addition of Radiolabeled Treatments Improve Outcomes in Advanced Metastatic Disease?

New Rochelle, NY--Radiolabeled agents are powerful tools for targeting and killing cancer cells and may help improve outcomes and lengthen survival times of patients with advanced disease that has spread beyond the initial tumor site. Effective therapy for metastatic cancer requires a combination of treatments, and the benefits of adding radionuclide therapy are explored in three studies published in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers at liebertpub.com. The articles are available on the Cancer Biotherapy and Radiopharmaceuticals website at liebertpub.com/cbr.

"The preliminary therapeutic results reported in these case studies using radionuclide multimodality approaches are encouraging,” says Co-Editor-in-Chief Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham. "The outcomes described in these small, single center studies must be confirmed in larger trials before they can be translated into widespread oncology practice."

J. Harvey Turner, MD, FRACP, The University of Western Australia, Fremantle, coauthored two of the case studies and, in the Perspective article "Multimodality Radionuclide Therapy of Progressive Disseminated Lymphoma and Neuroendocrine Tumors as a Paradigm for Cancer Control," he states that the synergistic effects that can be achieved by combining chemotherapy and radionuclides "has the potential to enhance efficacy and minimize toxicity." Although advanced forms of lymphoma and neuroendocrine tumors are usually incurable, multimodal treatment approaches may be able to stop or slow tumor progression, achieve durable remission, prolong patient survival, and improve their quality of life.

Paul Kruger, Julian Cooney, and J. Harvey Turner report that more patients survived longer and were free of disease when a radioimmunotherapeutic agent was added to their treatment regimen in the article "Iodine-131 Rituximab Radioimmunotherapy with BEAM Conditioning and Autologous Stem Cell Transplant Salvage Therapy for Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma."

Phillip Claringbold, Richard Price, and J. Harvey Turner added a lutetium-177 labeled peptide to the therapeutic regimen of a group of patients with advanced neuroendocrine cancer and described substantially improved tumor control rates with no significant side effects. They report their findings in "Phase I-II Study of Radiopeptide 177Lu-Octreotate in Combination with Capecitabine and Temozolomide in Advanced Low-Grade Neuroendocrine Tumors."

About the Journal
Cancer Biotherapy and Radiopharmaceuticals
(liebertpub.com/cbr), published 10 times a year in print and online, is under the editorial leadership of Editors Donald J. Buchsbaum, PhD, Division of Radiation Biology, Department of Radiation Oncology, University of Alabama at Birmingham, and Robert K. Oldham, MD, Lower Keys Cancer Center, Key West, FL. Cancer Biotherapy and Radiopharmaceuticals is the only journal with a specific focus on cancer biotherapy, including monoclonal antibodies, cytokine therapy, cancer gene therapy, cell-based therapies, and other forms of immunotherapy. The Journal includes extensive reporting on advancements in radioimmunotherapy and the use of radiopharmaceuticals and radiolabeled peptides for the development of new cancer treatments. Topics include antibody drug conjugates, fusion toxins and immunotoxins, nanoparticle therapy, vascular therapy, and inhibitors of proliferation signaling pathways.

About the Publisher
Mary Ann Liebert, Inc., publishers
is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Interferon & Cytokine Research, Human Gene Therapy and Human Gene Therapy Methods, and Stem Cells and Development. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 70 journals, books, and newsmagazines is available on Mary Ann Liebert, Inc., publishers website at liebertpub.com.

Photo:
http://www.prlog.org/12022201/1

--- End ---

Click to Share

Contact Email:
***@liebertpub.com Email Verified
Source:Mary Ann Liebert, Inc., publishers
Phone:914-740-2100
Zip:10801
City/Town:New Rochelle - New York - United States
Industry:Medical, Science
Tags:metastic cancer, chemotherapy, lymphoma
Shortcut:prlog.org/12022201
Disclaimer:   Issuers of the press releases are solely responsible for the content of their press releases. PRLog can't be held liable for the content posted by others.   Report Abuse

Latest Press Releases By “

More...

Trending News...



  1. SiteMap
  2. Privacy Policy
  3. Terms of Service
  4. Copyright Notice
  5. About
  6. Advertise
Like PRLog?
9K2K1K
Click to Share